S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:ALLK

Allakos Stock Forecast, Price & News

$79.00
-1.09 (-1.36%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$78.04
$81.13
50-Day Range
$79.41
$110.43
52-Week Range
$75.41
$157.98
Volume
351,642 shs
Average Volume
249,648 shs
Market Capitalization
$4.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.71
30 days | 90 days | 365 days | Advanced Chart
Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.


Allakos logo

About Allakos

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.

Headlines

Allakos (NASDAQ:ALLK) Shares Gap Down to $92.66
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
125
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$9.66 per share

Profitability

Net Income
$-153.48 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
35,602,000
Market Cap
$4.29 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank

Overall MarketRank

2.34 out of 5 stars

Medical Sector

237th out of 1,392 stocks

Pharmaceutical Preparations Industry

102nd out of 670 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Allakos (NASDAQ:ALLK) Frequently Asked Questions

Is Allakos a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Allakos stock.
View analyst ratings for Allakos
or view top-rated stocks.

How has Allakos' stock been impacted by Coronavirus?

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLK stock has increased by 35.5% and is now trading at $79.00.
View which stocks have been most impacted by COVID-19
.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Allakos
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Monday, November, 8th. The company reported ($1.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.12) by $0.04.
View Allakos' earnings history
.

What price target have analysts set for ALLK?

6 brokerages have issued 12 month target prices for Allakos' stock. Their forecasts range from $76.53 to $230.00. On average, they expect Allakos' stock price to reach $151.11 in the next year. This suggests a possible upside of 91.3% from the stock's current price.
View analysts' price targets for Allakos
or view top-rated stocks among Wall Street analysts.

Who are Allakos' key executives?

Allakos' management team includes the following people:
  • Robert Alexander, Chief Executive Officer & Director
  • Adam L. Tomasi, President & Chief Operating Officer (LinkedIn Profile)
  • Harlan Baird Radford, Chief Financial Officer
  • Craig Paterson, Chief Medical Officer
  • Ruby Casareno, Vice President-Technical Operations

What other stocks do shareholders of Allakos own?

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by many different institutional and retail investors. Top institutional investors include Capital World Investors (12.18%), Capital Research Global Investors (9.04%), Wellington Management Group LLP (7.03%), BlackRock Inc. (5.25%), Janus Henderson Group PLC (1.81%) and Alliancebernstein L.P. (1.25%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends for Allakos
.

Which institutional investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, BlackRock Inc., Point72 Asset Management L.P., Two Sigma Investments LP, Morgan Stanley, Handelsbanken Fonder AB, Voloridge Investment Management LLC, and Two Sigma Advisers LP. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More, and Steven P James.
View insider buying and selling activity for Allakos
or view top insider-selling stocks.

Which institutional investors are buying Allakos stock?

ALLK stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, ArrowMark Colorado Holdings LLC, Wellington Management Group LLP, Alliancebernstein L.P., Caption Management LLC, Jennison Associates LLC, Capital World Investors, and Goldman Sachs Group Inc..
View insider buying and selling activity for Allakos
or or view top insider-buying stocks.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $79.00.

How much money does Allakos make?

Allakos has a market capitalization of $4.29 billion. The company earns $-153.48 million in net income (profit) each year or ($4.13) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 125 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

Where are Allakos' headquarters?

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 597-5002 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.